Navigation Links
Biomarker predicts effectiveness of brain cancer treatment
Date:7/1/2014

Researchers at the University of California, San Diego School of Medicine have identified a new biomarker that predicts whether glioblastoma the most common form of primary brain cancer will respond to chemotherapy. The findings are published in the July print issue of Oncotarget.

"Every patient diagnosed with glioblastoma is treated with a chemotherapy called temozolomide. About 15 percent of these patients derive long-lasting benefit," said Clark C. Chen, MD, PhD, vice-chairman of Academic Affairs, Division of Neurosurgery, UC San Diego School of Medicine and the study's principal investigator. "We need to identify which patients benefit from temozolomide and which another type of treatment. All therapies involve risk and the possibility of side-effects. Patients should not undergo therapies if there's no likelihood of benefit."

To pinpoint which patients were most likely respond to temozolomide, the researchers studied microRNAs that control the expression of a protein called methyl-guanine-methyl-transferase or MGMT. This protein dampens the cancer-killing effect of temozolomide. Tumors with high levels of MGMT are associated with a poor response to temozolomide therapy.

The scientists systematically tested every microRNA in the human genome to identify those that suppressed MGMT expression, with the expectation that high-levels of these microRNAs in the tumor would predict improved therapeutic response to temozolomide.

"We showed that a signature of the MGMT-regulating microRNAs predicted temozolomide response in a cohort of glioblastoma patients. Validation of these results should lead to diagnostic tools to enable us to determine which patients will benefit most from temozolomide therapy," said Chen.

In the study, the scientists also discovered that injection of the MGMT-regulating microRNAs into glioblastoma cells increased tumor sensitivity to temozolomide treatment.

"These findings establish the foundation for microRNAs-based therapies to increase the efficacy of temozolomide in glioblastoma patients," said lead author, Valya Ramakrishnan, PhD, postdoctoral researcher, UC San Diego School of Medicine.


'/>"/>

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
2. Biomarkers can reveal IBS
3. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
4. Early biomarker for pancreatic cancer identified
5. New biomarker test predicts arthritis at much earlier stage, MU researchers say
6. Biomarker predicts response to cancer treatment
7. Novel biomarkers reveal evidence of radiation exposure
8. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
9. Using biomarkers to identify and treat schizophrenia
10. US Army: Pre-injury cartilage biomarkers associated with subsequent ACL injuries
11. Biomarkers of behavior, therapeutic targets for adult B-acute lymphoblastic leukemia identified
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarker predicts effectiveness of brain cancer treatment
(Date:3/22/2017)... Angeles, California (PRWEB) , ... March 22, 2017 , ... ... signed British boxing champ Ashley Theophane as a new Brand Ambassador. Theophane, who trained ... British light welterweight title in 2011. He has racked up an impressive number of ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... announced that its digital marketing solutions have enabled Children’s Hospital of The King’s ... months. , Recognizing the value of a digital marketing approach, the 206-bed ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... research collaboration to translate advances in basic neuroscience at the BMRI labs into ... collaboration seeks to improve movement, vision, and cognition impaired by stroke, traumatic brain ...
(Date:3/22/2017)... ... 2017 , ... The Vanderbeck Agency, a Long Island firm providing insurance, financial ... on a combined charity effort with the Great Neck Breast Cancer Coalition to provide ... Great Neck Breast Cancer Coalition has worked to support breast cancer patients in the ...
(Date:3/22/2017)... ... ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection services and ... initiating a charity event to raise support for five year old Dillyn, a young ... Friday evening in September 2014. At the time, Dillyn was only four years old, ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Under the ... pharmaceutical packaging market size increased year by year ... 2017 to 2021, the market size will maintain ... expected to outnumber RMB140 billion in 2021, thanks ... rapid development of biological agents and supporting policies. ...
(Date:3/22/2017)...  ImaginAb Inc. today announced the appointment of Martyn Coombs ... , chairman of ImaginAb, said "At ImaginAb we have exciting science ... relevant to our business, particularly in commercializing and making step changes ... we can realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear ...
(Date:3/22/2017)... 2017  CANTEL MEDICAL CORP. (NYSE: CMD ) ... CEO, will be presenting at the 16 th Annual ... Hotel in New York . The formal ... p.m. ET. In addition, management will be available for separate ... audio webcast will be available via the investor relations page ...
Breaking Medicine Technology: